Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.
It’s getting harder to claim success with weight reduction drugs
Novo Nordisk’s obesity drug CagriSema’s test results showed an average weight loss of over 20%, but its stock slid in ...
Novo's next-gen obesity drug candidate trial disappoints
Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their ...
Novo Nordisk Stock Crashes on Obesity Drug Data. It’s a Win for Eli Lilly.
Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...
Investing22d
Structure Therapeutics holds overweight rating on pre-clinical efficacy
Structure Therapeutics is preparing to begin ... Furthermore, GPCR anticipates that upcoming results from their CagriSema trials over the next year could further validate the mechanism of action ...
gulftoday13d
The bar for successful obesity drugs is rising
In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...